» Articles » PMID: 25774503

STAT3 Upregulation in Pituitary Somatotroph Adenomas Induces Growth Hormone Hypersecretion

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2015 Mar 17
PMID 25774503
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Pituitary somatotroph adenomas result in dysregulated growth hormone (GH) hypersecretion and acromegaly; however, regulatory mechanisms that promote GH hypersecretion remain elusive. Here, we provide evidence that STAT3 directly induces somatotroph tumor cell GH. Evaluation of pituitary tumors revealed that STAT3 expression was enhanced in human GH-secreting adenomas compared with that in nonsecreting pituitary tumors. Moreover, STAT3 and GH expression were concordant in a somatotroph adenoma tissue array. Promoter and expression analysis in a GH-secreting rat cell line (GH3) revealed that STAT3 specifically binds the Gh promoter and induces transcription. Stable expression of STAT3 in GH3 cells induced expression of endogenous GH, and expression of a constitutively active STAT3 further enhanced GH production. Conversely, expression of dominant-negative STAT3 abrogated GH expression. In primary human somatotroph adenoma-derived cell cultures, STAT3 suppression with the specific inhibitor S3I-201 attenuated GH transcription and reduced GH secretion in the majority of derivative cultures. In addition, S3I-201 attenuated somatotroph tumor growth and GH secretion in a rat xenograft model. GH induced STAT3 phosphorylation and nuclear translocation, indicating a positive feedback loop between STAT3 and GH in somatotroph tumor cells. Together, these results indicate that adenoma GH hypersecretion is the result of STAT3-dependent GH induction, which in turn promotes STAT3 expression, and suggest STAT3 as a potential therapeutic target for pituitary somatotroph adenomas.

Citing Articles

Targeting RACGAP1 suppresses growth hormone pituitary adenoma growth.

Sun F, Ji C, Zhou X, Zhang Y, Cheng H, Ye Z Endocrine. 2024; .

PMID: 39607642 DOI: 10.1007/s12020-024-04116-4.


Differential gene expression and pathway analysis in growth hormone-secreting pituitary tumors according to granulation pattern.

Kim K, Kim Y, Kim S, Moon J, Kim E, Lee E Front Oncol. 2024; 14:1423606.

PMID: 39139281 PMC: 11319302. DOI: 10.3389/fonc.2024.1423606.


Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.

Lin S, Wang L, Han C, Dai Y, Li C, Liu Y Neuro Oncol. 2024; 26(11):2010-2026.

PMID: 38989697 PMC: 11534325. DOI: 10.1093/neuonc/noae130.


The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.

Zhao R, Hu Z, Zhang X, Huang S, Yu G, Wu Z Cell Commun Signal. 2024; 22(1):68.

PMID: 38273295 PMC: 10809652. DOI: 10.1186/s12964-023-01421-9.


Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine.

Kim K, Ku C, Lee E Endocrinol Metab (Seoul). 2023; 38(5):463-471.

PMID: 37828709 PMC: 10613768. DOI: 10.3803/EnM.2023.1820.


References
1.
Herrington J, Smit L, Schwartz J . The role of STAT proteins in growth hormone signaling. Oncogene. 2000; 19(21):2585-97. DOI: 10.1038/sj.onc.1203526. View

2.
Starke R, Raper D, Payne S, Vance M, Oldfield E, Jane Jr J . Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013; 98(8):3190-8. DOI: 10.1210/jc.2013-1036. View

3.
Shimon I, Cohen Z, Ram Z, Hadani M . Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001; 48(6):1239-43; discussion 1244-5. DOI: 10.1097/00006123-200106000-00008. View

4.
Kreutzer J, Vance M, Lopes M, Laws Jr E . Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001; 86(9):4072-7. DOI: 10.1210/jcem.86.9.7819. View

5.
Turkson J, Ryan D, Kim J, Zhang Y, Chen Z, Haura E . Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001; 276(48):45443-55. DOI: 10.1074/jbc.M107527200. View